Inicio>>Analytical Standards>>1-Myristoyl-d7-2-hydroxy-sn-glycero-3-PC

1-Myristoyl-d7-2-hydroxy-sn-glycero-3-PC (Synonyms: 14:0-d7 Lyso-PC,1-Myristoyl-d7-sn-glycero-3-Phosphatidylcholine)

Catalog No.GC91784

1-Myristoyl-d7-2-hydroxy-sn-glycero-3-PC is intended for use as an internal standard for the quantification of 1-myristoyl-2-hydroxy-sn-glycero-3-PC by GC- or LC-MS.

Products are for research use only. Not for human use. We do not sell to patients.

1-Myristoyl-d7-2-hydroxy-sn-glycero-3-PC Chemical Structure

Cas No.: N/A

Tamaño Precio Disponibilidad Cantidad
500 µg
133,00 $
Disponible
1 mg
239,00 $
Disponible
5 mg
998,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

1-Myristoyl-d7-2-hydroxy-sn-glycero-3-PC is intended for use as an internal standard for the quantification of 1-myristoyl-2-hydroxy-sn-glycero-3-PC by GC- or LC-MS. 1-Myristoyl-2-hydroxy-sn-glycero-3-PC is a saturated 14:0 lysophosphatidylcholine that consists of one chain of myristic acid at the sn-1 position. It is formed in plasma by lecithin:cholesterol acyltransferase (LCAT) and has a role in lipid signaling by acting on lysophospholipid receptors.[1]

References:
[1].Soupene, E., Fyrst, H., and Kuypers, F.A.Mammalian acyl-CoA:lysophosphatidylcholine acyltransferase enzymesProc. Natl. Acad. Sci. USA105(1)88-93(2008).

Reseñas

Review for 1-Myristoyl-d7-2-hydroxy-sn-glycero-3-PC

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 1-Myristoyl-d7-2-hydroxy-sn-glycero-3-PC

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.